{"id":69032,"date":"2026-06-29T20:51:29","date_gmt":"2026-06-29T12:51:29","guid":{"rendered":"https:\/\/flcube.com\/?p=69032"},"modified":"2026-06-29T20:51:30","modified_gmt":"2026-06-29T12:51:30","slug":"jjs-tecvayli-daratumumab-combo-receives-chmp-recommendation-for-earlier-multiple-myeloma-treatment-line","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69032","title":{"rendered":"J&amp;J&#8217;s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Johnson &amp; Johnson (J&amp;J, <a href=\"https:\/\/www.google.com\/finance\/quote\/JNJ:NYSE\">NYSE: JNJ<\/a>)<\/strong> announced on June 26, 2026, that the <strong>Committee for Medicinal Products for Human Use (CHMP)<\/strong> of the <strong>European Medicines Agency (EMA)<\/strong> has issued a positive opinion recommending approval of an <strong>indication extension<\/strong> for <strong>TECVAYLI (teclistamab)<\/strong> in combination with <strong>daratumumab<\/strong> for treating <strong>adult patients with relapsed or refractory multiple myeloma (RRMM)<\/strong> who have received <strong>at least one prior therapy<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-timeline\" class=\"wp-block-heading\">Regulatory Milestone Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Date<\/th><th>Regulatory Action<\/th><th>Indication<\/th><\/tr><\/thead><tbody><tr><td><strong>Aug 2022<\/strong><\/td><td>EC Approval<\/td><td>RRMM patients with \u22653 prior therapies (IMiD, PI, anti-CD38)<\/td><\/tr><tr><td><strong>Aug 2023<\/strong><\/td><td>EC Type II Variation<\/td><td>Reduced dosing frequency (1.5mg\/kg every 2 weeks) for CR+ patients \u22656 months<\/td><\/tr><tr><td><strong>Jun 2026<\/strong><\/td><td>CHMP Positive Opinion<\/td><td>Combination with daratumumab for \u22651 prior therapy patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Teclistamab:<\/strong> Bispecific antibody targeting <strong>BCMA<\/strong> (B-cell maturation antigen) and <strong>CD3<\/strong> (T-cell receptor)<\/li>\n\n\n\n<li><strong>Daratumumab:<\/strong> <strong>CD38-directed monoclonal antibody<\/strong> with complementary mechanism of action<\/li>\n\n\n\n<li><strong>Combination Rationale:<\/strong> Dual targeting enhances anti-myeloma activity through synergistic immune activation<\/li>\n\n\n\n<li><strong>Current Status:<\/strong> Already approved in EU for heavily pretreated RRMM patients<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-majestec-3-phase-3-study-nct05083169\" class=\"wp-block-heading\">Clinical Evidence \u2013 MajesTEC-3 Phase 3 Study (NCT05083169)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Teclistamab + Daratumumab<\/th><th>Standard of Care<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Progression-Free Survival<\/strong><\/td><td>Not reached<\/td><td>7.2 months<\/td><td><strong>Statistically significant improvement<\/strong><\/td><\/tr><tr><td><strong>Overall Survival<\/strong><\/td><td>Ongoing analysis<\/td><td>Reference arm<\/td><td><strong>Statistically significant improvement<\/strong><\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>\u22651 prior therapy<\/td><td>Same criteria<\/td><td>Earlier treatment line<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>MajesTEC-3 study<\/strong> demonstrated that the combination achieved <strong>statistically significant improvements<\/strong> in both progression-free survival (PFS) and overall survival (OS) compared to standard of care in patients with fewer prior treatment lines than previously approved.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-significance\" class=\"wp-block-heading\">Market Impact &amp; Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Expanded Patient Population:<\/strong> Moves treatment into earlier disease setting (\u22651 prior therapy vs. \u22653 prior therapies)<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Strengthens J&amp;J&#8217;s position in the growing BCMA-targeted multiple myeloma market<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Earlier-line treatment typically captures larger patient populations and longer treatment durations<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> European Commission decision expected within 67 days of CHMP recommendation<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Supports broader development program for teclistamab combinations across treatment lines<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This indication extension represents a significant advancement in making this innovative bispecific therapy available to patients earlier in their treatment journey, potentially improving long-term outcomes in multiple myeloma.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical trial results, and commercial expectations. Actual results may differ due to regulatory decisions, competitive developments, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced on June 26, 2026, that the Committee for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[29,150,149,38,28,858],"class_list":["post-69032","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-combination-therapy","tag-jj","tag-johnson-johnson","tag-market-approval-filings","tag-multi-specific-antibodies","tag-nyse-jnj"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>J&amp;J&#039;s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced on June 26, 2026, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of an indication extension for TECVAYLI (teclistamab) in combination with daratumumab for treating adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69032\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"J&amp;J&#039;s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line\" \/>\n<meta property=\"og:description\" content=\"Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced on June 26, 2026, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of an indication extension for TECVAYLI (teclistamab) in combination with daratumumab for treating adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69032\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-29T12:51:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-29T12:51:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69032#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69032\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"J&amp;J&#8217;s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line\",\"datePublished\":\"2026-06-29T12:51:29+00:00\",\"dateModified\":\"2026-06-29T12:51:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69032\"},\"wordCount\":377,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Combination therapy\",\"J&amp;J\",\"Johnson &amp; Johnson\",\"Market approval filings\",\"Multi-specific antibodies\",\"NYSE: JNJ\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69032#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69032\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69032\",\"name\":\"J&amp;J's TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-29T12:51:29+00:00\",\"dateModified\":\"2026-06-29T12:51:30+00:00\",\"description\":\"Johnson & Johnson (J&J, NYSE: JNJ) announced on June 26, 2026, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of an indication extension for TECVAYLI (teclistamab) in combination with daratumumab for treating adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69032#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69032\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69032#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"J&amp;J&#8217;s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"J&amp;J's TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line - Insight, China&#039;s Pharmaceutical Industry","description":"Johnson & Johnson (J&J, NYSE: JNJ) announced on June 26, 2026, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of an indication extension for TECVAYLI (teclistamab) in combination with daratumumab for treating adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69032","og_locale":"en_US","og_type":"article","og_title":"J&amp;J's TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line","og_description":"Johnson & Johnson (J&J, NYSE: JNJ) announced on June 26, 2026, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of an indication extension for TECVAYLI (teclistamab) in combination with daratumumab for treating adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy.","og_url":"https:\/\/flcube.com\/?p=69032","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-29T12:51:29+00:00","article_modified_time":"2026-06-29T12:51:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69032#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69032"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"J&amp;J&#8217;s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line","datePublished":"2026-06-29T12:51:29+00:00","dateModified":"2026-06-29T12:51:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69032"},"wordCount":377,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Combination therapy","J&amp;J","Johnson &amp; Johnson","Market approval filings","Multi-specific antibodies","NYSE: JNJ"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69032#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69032","url":"https:\/\/flcube.com\/?p=69032","name":"J&amp;J's TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-29T12:51:29+00:00","dateModified":"2026-06-29T12:51:30+00:00","description":"Johnson & Johnson (J&J, NYSE: JNJ) announced on June 26, 2026, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of an indication extension for TECVAYLI (teclistamab) in combination with daratumumab for treating adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69032#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69032"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69032#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"J&amp;J&#8217;s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69032"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69032\/revisions"}],"predecessor-version":[{"id":69033,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69032\/revisions\/69033"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}